The "Yes" link below will take you out of the Abbott Laboratories family of websites.
Links which take you out of Abbott Laboratories worldwide web sites are not under the
control of Abbott Laboratories, and Abbott Laboratories is not responsible for the
contents of any such site or any further links from such site. Abbott Laboratories is
providing these links to you only as a convenience, and the inclusion of any link does
not imply endorsement of the linked site by Abbott Laboratories.

Do you wish to leave this site?
 

Coronary Bioresorbable Vascular Scaffolds

 

Overview

Absorb and Absorb GT1 - Bioresorbable Vascular Scaffold Systems

 

Abbott Absorb GT1

Absorb and Absorb GT1 are Bioresorbable Vascular Scaffold (BVS) systems which elute everolimus in a similar way to XIENCE V and then resorb naturally into the body leaving no permanent scaffold*. Absorb GT1 is an evolution of Absorb and comprises of four key design elements: a bioresorbable scaffold, a bioresorbable coating, everolimus and the Absorb GT1 enhanced delivery system.

 

Absorb GT1 Design Elements

 
Absorb GT1 Design Elements

AP2937989-WBO Rev. A

 

Absorb GT1 Design

Absorb GT1 Bioresorbable1 Scaffold Enhanced Catheter System Design

Absorb GT1 Design

 

Abbott Absorb GT1
Absorb GT1 bioresorbable 2 scaffold:
A better future for more patients
  •      Improved ease of use1 and broad patient applicability
  •      Proven safety and efficacy with over 100,0002 patients treated
  •      Restored vessel function3 and reduced late events4

Three generations of innovations to develop the robust and easy-to-use Absorb GT1 catheter

Advancements In Stent Design

Absorb GT1 - advanced catheter design allows for greater application among a broad coronary patient population

These tip-to-hub advancements facilitate treatment in more patients.

Absorb GT1 Catheter Features

The Absorb GT1 bioresorbable scaffold catheter system is available in 14 different diameters

 

Absorb GT1 ordering information

Absorb GT1 Diameters and Lengths

 


 

Absorb ordering information

Absorb Scaffold Ordering Information

1. Improved as compared to Absorb BVS. Tests performed by and data on file at Abbott Vascular. 2. Based on worldwide device utilization rate. Data on file at Abbott Vascular as of April 2015. 3. De Bruyne B, Serruys PW, et al., for the ABSORB Cohort B Investigators, TCT 2014. 4. Smits P. EXTEND 3 Year Presentation. Presented at TCT 2014, 13-17 Sep 2014, Washington, DC.

AP2937989-WBO Rev. A

Absorb GT1 Patient Outcomes

Absorb GT1: Addressing the need to further improve PCI outcomes for patients

The Absorb GT1 bioresorbable scaffold addresses the need to further improve percutaneous coronary intervention (PCI) outcomes for patients

Absorb GT1 Benefits
  • Best-in-class permanent stent cannot reduce the occurrence of events over time1
    • -Over a 5-year period, adverse clinical events continued to increase in patients with a permanent stent1
  • Arteries without a permanent stent show lower event rates over the long term2
  • Absorb bioresorbable scaffold pairs the short-term benefits of an implant with the long-term benefits of an uncaged artery.3-5

Absorb GT1: Improving long-term patient outcomes4

Absorb’s observed unique long-term clinical benefits:

  • Reduction of late events4
  • Restored vessel function6
  • Reduced revascularization rates7
  • Plague regression3
  • Lumen gain8,9
Absorb GT1 Long-term BenefitsAbsorb GT1 Long-term Clinical Benefits

Absorb: Extensive experience in over 100,000 patients...

Absorb GT1 Clinical Trial Program

Absorb Bioresorbable Scaffold Clinical trial program

Absorb – Real world and complex patient populations

Including patients with ACS, MI, Acute STEMI, diabetes,and complex lesions, including bifurcations and CTOs

Absorb GT1 Clinical Trial Design

ABSORB Cohort B – Imaging at 5 Years *Sources: Dr. G. Stone, Bioresorbable Vascular Scaffold: Acute Performance and Safety Symposia, EuroPCR 2014 and www.clinicaltrials.gov.

ACS, acute coronary syndrome; MVD, multi-vessel disease; CTO, chronic total occlusion; MI, myocardial infarction RCT, randomized controlled trial; OMT, optimal medical therapy; EES, everolimus-eluting stents; BVS, bioresorbable vascular scaffold; STEMI, ST-segment–elevation myocardial infarction; MACE, major adverse cardiac events; ID-MACE, ischaemia-driven major adverse cardiac events; TLF, target lesion failure; IVUS MLA, intravascular ultrasound minimal lumen area; TVF, target vessel failure; LAD, left anterior descending; FIM, first-in-man.

1. Gada H, et al. JACC: Cardiovascular Interventions. 2013;6:1263-6; 2. Brodie BR, et al, J IntervenCardiol. 2014:27:21-28; 3. Serruys PW, et al. EuroIntervention. 2014;9(11):1271-84; 4. Smits P. EXTEND 3 Year Presentation. Presented at TCT 2014, 13-17 Sep 2014, Washington, DC; 5. Serruys PW, et al. Lancet. 2015;385(9962):43-54; 6. ABSORB Cohort B trial; De Bruyne B, Serruys PW, etal., for the ABSORB Cohort B Investigators, TCT 2014; 7. Serruys P. ABSORB II 1 Year Presentation. Presented at TCT 2014,13-17 Sep 2014, Washington, DC;8. Serruys, PW. ABSORB Cohort B, 2-year results, TCT 2011; 9. Serruys PW, ABSORB Cohort B, 3-year results, ACC 2013. 10. Based on worldwide device utilization rate. Data on file at Abbott Vascular as of April 2015;11. Data on file at Abbott Vascular. 12. Excludes STEMI patients

AP2937989-WBO Rev. A

Absorb GT1 Product Ordering Info

Absorb GT1 Ordering Information

Absorb GT1 Diameters and Lengths

 

AP2937989-WBO Rev. A

Absorb Product Ordering Info

Absorb Ordering Information

Absorb Scaffold Ordering Information

 

AP2937989-WBO Rev. A